Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Eli Lilly and Company & Sun Pharma

4 shared events · Importance 3 · Last updated Jul 22, 2026

Importance
3
Shared Events
4
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
53
Domestic
Eli Lilly and Company: Eli Lilly was among the earlier drugmakers that agreed to MFN pricing, contributing to the administration's drug pricing push.
Sun Pharma: Sun Pharma extended MFN pricing to United States — Medicaid and future launches, gaining a two-year tariff reprieve. The deal supports its planned $11.75 billion acquisition of Organon & Co., though shares dipped about 1%.
Aug 18, 2026 · 37 articles
35
Regulatory
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in India's obesity-drug market with Mounjaro; the approval may intensify competition.
Sun Pharma: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
20
Business
Eli Lilly and Company: Eli Lilly's Olumiant is a competitor JAK inhibitor for alopecia areata; positive bempikibart data may increase competition.
Sun Pharma: Sun Pharma's Leqselvi is a competitor JAK inhibitor; potential competitive pressure from bempikibart.
Jul 13, 2026 · 6 articles
0
Business
Mar 20, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Eli Lilly and Company and Sun Pharma interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.